Ionis Pharmaceuticals (IONS) Misses Q4 EPS by $2.72, Revenues Beat; Offers FY21 Revenue Guidance Below Consensus
- S&P 500, Dow edge lower as COVID-19 cases rise, home sales drop
- Credit Suisse (CS) Falls 6% on 'Unacceptable Loss' as Exposure to Archegos Grew to More Than $20 Billion, Set to Raise Over $2 Billion to Support Liquidity
- U.S. weekly jobless claims fall to new one-year low
- Cathie Wood's ARK Buys Over 5M Shares of Skillz (SKLZ), Nearly 3M Shares of IPO UiPath (PATH)
- Chipotle Mexican Grill (CMG) Tops Q1 Profit Views, Analysts Maintain Bullishness For 2021
Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.
Ionis Pharmaceuticals (NASDAQ: IONS) reported Q4 EPS of ($2.44), $2.72 worse than the analyst estimate of $0.28. Revenue for the quarter came in at $290 million versus the consensus estimate of $274.48 million.
"Last year, we laid out a bold new vision for the Company and took important steps towards our goal of becoming one of the most successful biotechnology companies. Key to our vision is our strategy to maximize the value of our pipeline by commercializing our wholly owned medicines. Our acquisition of Akcea was an important step in building our commercial capabilities while enabling us to further strengthen our organization," said Brett P. Monia, Ph.D., chief executive officer at Ionis. "Last year, we also advanced our late-stage pipeline and expanded the utility of our technology. Looking ahead, we expect data from multiple wholly owned programs in the first half of this year, followed by Phase 3 tofersen data in patients with SOD1-ALS in the second half. These key upcoming catalysts, together with our recent pipeline and technology achievements, position us well to have 12 or more products on the market in 2026. Importantly, we continue to have the financial strength to expand investment in our wholly owned pipeline and commercial capabilities to drive meaningful and increasing value for patients and shareholders."
Ionis Pharmaceuticals sees FY2021 revenue of $600 million, versus the consensus of $781.31 million.
"We achieved our 2020 financial guidance, even in the challenging COVID-19 pandemic environment. Moreover, in 2020 we made significant progress toward our goal of creating a stronger, more efficient company focused primarily on advancing our wholly owned medicines to the market. We acquired Akcea enabling us to retain full value from its rich portfolio. We also restructured our European operations. Together, these transactions unlocked substantial cost savings that we plan to reinvest to drive future revenue growth," said Elizabeth L. Hougen, chief financial officer of Ionis. "Our 2021 guidance reflects our new strategy to maximize the value of our wholly owned pipeline, focused primarily on commercializing our rare neurological and cardiometabolic disease programs. Our guidance also reflects the investments we are making in three key areas of our business - advancing and expanding our wholly owned pipeline, building commercial capabilities in support of our rich pipeline and broadening the reach of our technology. We can increase our investments in these areas while only modestly increasing our expenses because of the significant cost savings we realized from acquiring Akcea and restructuring our European operations. Importantly, with nearly $2 billion of cash at the end of last year, we remain well capitalized with the substantial financial resources to achieve our goals."
For earnings history and earnings-related data on Ionis Pharmaceuticals (IONS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Genuine Parts (GPC) Tops Q1 EPS by 36c, Revenues Beat; Raises FY21 EPS Guidance Above Consensus
- Magellan Midstream Partners (MMP) Reports Sale of Partial Interest in Pasadena Marine Terminal J.V.
- FuelCell Energy (FCEL) Celebrates Earth Day; Announces Significant 12 Million MWH Generated Milestone
Create E-mail Alert Related CategoriesCorporate News, Earnings, Guidance, Management Comments
Related EntitiesEarnings, Definitive Agreement
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!